Nasdaq moves to delist Crinetics Pharmaceuticals
Rhea-AI Filing Summary
Crinetics Pharmaceuticals, Inc. (CRNX) has had its common stock the subject of a Form 25 filing by Nasdaq Stock Market LLC to remove the class of securities from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The notification states that the exchange has complied with its rules and with 17 CFR 240.12d2-2(b), and that the issuer has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing withdrawal of the class from listing and registration. The filing is signed on behalf of Nasdaq by an authorized officer.
Positive
- None.
Negative
- None.
Key Figures
Issuer telephone number: 858-703-6540
Zip code of principal executive offices: 92121
Commission File Number: 001-38583
3 metrics
Issuer telephone number
858-703-6540
Telephone number for Crinetics Pharmaceuticals, Inc. principal executive offices
Zip code of principal executive offices
92121
ZIP code for Crinetics Pharmaceuticals, Inc. address in San Diego, California
Commission File Number
001-38583
Exchange Act registration file number for Crinetics Pharmaceuticals, Inc.
Key Terms
Form 25, Section 12(b) of the Securities Exchange Act of 1934, 17 CFR 240.12d2-2, withdrawal of the class of securities from listing and registration
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) of the Securities Exchange Act of 1934 regulatory
"under SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
withdrawal of the class of securities from listing and registration regulatory
"governing the voluntary withdrawal of the class of securities from listing"
FAQ
What does the Form 25 filed for CRNX common stock mean?
The Form 25 indicates that Crinetics Pharmaceuticals, Inc. common stock is being removed from listing and/or registration under Section 12(b) of the Exchange Act. Nasdaq Stock Market LLC certifies it has followed its rules and applicable 17 CFR 240.12d2-2 procedures.
Which securities of CRNX are covered by this Form 25?
The filing covers Common Stock of Crinetics Pharmaceuticals, Inc. listed on Nasdaq Stock Market LLC, and serves as notification of its removal from listing and/or registration under Section 12(b).
What regulations are cited in the CRNX Form 25 notice?
The notice references 17 CFR 240.12d2-2(a)(1)-(4), and states compliance with 17 CFR 240.12d2-2(b) by the exchange and 17 CFR 240.12d2-2(c) by the issuer for withdrawal of the class from listing and registration.
What is the issuer information for CRNX in the Form 25?
The issuer is Crinetics Pharmaceuticals, Inc., with principal executive offices at 10222 Barnes Canyon Road, Bldg. #2, San Diego, California 92121, and telephone number 858-703-6540, as stated in the notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
